Home Media Library Press Press Releases Press Releases +++ Renowned Peutinger-Collegium visits the IZB ++++++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 ++++++ GoingPublic celebrates a quarter century of biotech ++++++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency ++++++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell ++++++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology ++++++ High-Profile Clinical Advisory Board for Thermosome ++++++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker ++++++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation ++++++ adivo becomes part of the world’s leading animal health company Zoetis ++++++ The Munich Bavaria Student Union visits the IZB ++++++ Bind-X secures €10 million in financing as part of its Series B financing round ++++++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research ++++++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program ++++++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub ++++++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy ++++++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease ++++++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO ++++++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB ++++++ Japanese delegation visits the IZB ++++++ Bavarian biotechnology maintains its position in the crisis and continues to grow ++++++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board ++++++ Official handover ceremony at the Annual Meeting of the Max Planck Society ++++++ Secarna appoints new Chief Business Officer ++++++ Bicoll showcases at BIO International Convention ++++++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma ++++++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry ++++++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies ++++++ Biotech report by vfa: Biopharmaceuticals successfully gain market share ++++++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa ++++++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics ++++++ Non-nutritive sweeteners may affect the human immune system ++++++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” ++++++ Invitris receives 250,000 EUR to complete spin-out from TUM ++++++ Eisbach starts phase I clinical trial with COVID-19 antiviral ++++++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park ++++++ Specific packaging of DNA affects cell division ++++++ Tubulis Enters Strategic Partnership with BMS ++++++ Insempra launches its first functional component for consumer goods ++++++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman ++++++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease ++++++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership ++++++ adivo expands into new headquarters as first clinical study begins ++++++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial ++++++ Construction of the “New Hauner” at the Grosshadern Campus has started ++++++ Insempra names new Chief Operating Officer ++++++ Training events for project managers and biological safety officers ++++++ The zebrafish brain as a map ++++++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure ++++++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris ++++++ When life begins too early ++++++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease ++++++ Expansion of the Munich “science line” has started ++++++ Enno Spillner to join Formycon as CFO +++ PDF archive 2018 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 14. June 2018Innovative start-ups present to leading life science investors at the IZB 26. May 2018New ways to invest in cancer drugs 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer 15. March 2018Origenis Appoints Thomas Loeser as Chief Financial Officer 8. February 2018New Technologies from the IZB are revolutionizing medical diagnostics 5. September 2017Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million 6. July 2017Start-ups profit from being in close contact with the venture capital scene 2017 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 14. June 2018Innovative start-ups present to leading life science investors at the IZB 26. May 2018New ways to invest in cancer drugs 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer 15. March 2018Origenis Appoints Thomas Loeser as Chief Financial Officer 8. February 2018New Technologies from the IZB are revolutionizing medical diagnostics 5. September 2017Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million 6. July 2017Start-ups profit from being in close contact with the venture capital scene
